Short answer
SELLAS Life Sciences Group, Inc. (SLS) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for quarter ended September 30, 2026.
SELLAS Life Sciences Group, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Corporate update accompanies results, with substantive details in Exhibit 99.1
- Investor focus: cash position, clinical-program progress, and financing outlook in the press release
Item EX-99.1 · Exhibit EX-99.1
- Q3 2026 results and corporate update: primary REGAL endpoint data for GPS expected in November
- REGAL reached the prespecified 80th event, triggering final analysis and unblinding procedures
- SLS009 Phase 2 enrollment reached 40 of 80 patients, with preliminary topline data expected Q4 2026
- Prior SLS009 data showed 54% ORR in relapsed/refractory monocytic AML and 57% ORR in TP53-mutated AML
- Cash $134.7M at September 30, 2026, while Q3 net loss widened to $10.1M from $6.8M; R&D rose to $7.0M from $4.2M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other SELLAS Life Sciences Group, Inc. 8-K filings
Get the next SLS 8-K as it lands
Follow SLS for push alerts, or ask the research agent what this filing means.